Show simple item record

dc.contributor.supervisor Dr. Spencer Gibson (Immunology). en_US
dc.contributor.author Liu, Elaine
dc.date.accessioned 2012-03-12T18:57:18Z
dc.date.available 2012-03-12T18:57:18Z
dc.date.issued 2012-03-12
dc.identifier.uri http://hdl.handle.net/1993/5174
dc.description.abstract Chronic lymphocytic leukemia (CLL) is presently an incurable disease that is expected to increase in prevalence, as a result of the aging population. Currently, the standard treatment used is chlorambucil or fludarabine, combined with cyclophosphamide and rituximab. The disease has a variable course. Recently, it has been shown that the expression of the tyrosine kinase, ZAP-70 in CLL is a strong indicator of poor prognosis, with a greatly reduce time to treatment from diagnosis, compared with ZAP-70 negative patients. Therefore, therapy that specifically targets ZAP-70 positive CLL might improve these patients’ outcomes. The tyrosine kinase inhibitor gefitinib has been shown to reduce the phosphorylation levels of several tyrosine kinases including ZAP-70 and SYK. We treated several ZAP-70 positive and ZAP-70 negative patient samples with gefitinib and found that gefitinib had a much lower IC 50 for ZAP-70 positive patients than it did for ZAP-70 negative patients. Also, gefitinib induced more apoptosis in the ZAP-70 positive cell line Jurkat than it did in cells lines not expressing ZAP-70. These results support a role for gefitinib in the treatment of ZAP-70 positive CLL. en_US
dc.subject medicine en_US
dc.title Gefitinib as a Potential Treatment for Aggressive CLL en_US
dc.degree.discipline Medicine en_US
dc.contributor.examiningcommittee Medicine en_US
dc.degree.level Bachelor of Science (B.Sc.) en_US
dc.description.note October 2011 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics